Research programme: CCR6 pathway modulators - BiokineAlternative Names: BKT150
Latest Information Update: 29 Jan 2016
At a glance
- Originator Biokine Therapeutics
- Mechanism of Action Chemokine modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 29 Jan 2016 Discontinued for Cancer in Israel (IV)
- 29 Jan 2016 Discontinued for Autoimmune disorders in Israel (IV)
- 07 Jul 2011 Early research in Cancer in Israel (IV)